Protara Therapeutic (TARA)
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare disea...
- Open
- 4.000
- High
- 4.030
- Low
- 3.850
- Prev. Close
- 4.110
- Volume
- 618.12K
- Turnover
- 2.43M
- Avg Price
- 3.932
- Bid/Ask Ratio
- 17.01%
- Amplitude
- 4.38%
- 52wk High
- 7.820
- Volume Ratio
- 1.48
- Turnover Ratio
- 1.26%
Protara Therapeutic Analyst Rating
View moreForecast & Rating
Aug 11, 2026Price forecast
$25.71557.65%
Forecast & RatingStrong buy
8analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · 10 hours ago
Protara Therapeutics: Strategic Trial Shift and Strong Cash Runway Support Buy Rating Despite Price Target Cut to $20 From $26
- TradingView · 21 hours ago
Protara Therapeutics, Inc. 2Q 2026: Net income $(21.7) M, EPS $(0.36) — 10-Q Summary
- Earnings Watch · 21 hours ago
Protara Therapeutic | 8-K: FY2026 Q2 Revenue: USD 0
- Unusual Whales · 21 hours ago
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
- PUBT · Jul 1 at 03:11 PM
Protara Therapeutics CEO Jesse Shefferman disposes of 215,687 common shares for $882,156.83
- PUBT · Jun 29 at 04:03 PM
Protara Therapeutics CMO Nicacio resigns effective June 26, 2026
